ZEPP Fundamental Analysis - ZEPP HEALTH CORP-ADR

Name: ZEPP HEALTH CORP-ADR (ZEPP) Stock
Brand: ZEPP HEALTH CORP-ADR
Rating: 5 (3 reviews)

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to ZEPP. ZEPP was compared to 124 industry peers in the Electronic Equipment, Instruments & Components industry. ZEPP may be in some trouble as it scores bad on both profitability and health. ZEPP is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ZEPP has reported negative net income.

The reported net income has been mixed in the past 5 years: ZEPP reported negative net income in multiple years.

The reported operating cash flow has been mixed in the past 5 years: ZEPP reported negative operating cash flow in multiple years.

1.2 Ratios

ZEPP has a Return On Assets of -14.18%. This is in the lower half of the industry: ZEPP underperforms 66.94% of its industry peers.

ZEPP has a worse Return On Equity (-34.61%) than 71.77% of its industry peers.

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROIC	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ZEPP has a Gross Margin of 37.59%. This is in the better half of the industry: ZEPP outperforms 62.90% of its industry peers.

ZEPP's Gross Margin has improved in the last couple of years.

ZEPP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	37.59%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZEPP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ZEPP has less shares outstanding

Compared to 5 years ago, ZEPP has less shares outstanding

Compared to 1 year ago, ZEPP has a worse debt to assets ratio.

2.2 Solvency

ZEPP has an Altman-Z score of 4.47. This indicates that ZEPP is financially healthy and has little risk of bankruptcy at the moment.

With a decent Altman-Z score value of 4.47, ZEPP is doing good in the industry, outperforming 64.52% of the companies in the same industry.

ZEPP has a Debt/Equity ratio of 0.85. This is a neutral value indicating ZEPP is somewhat dependend on debt financing.

With a Debt to Equity ratio value of 0.85, ZEPP is not doing good in the industry: 87.10% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Altman-Z	4.47

ROIC/WACCN/A

WACC6.98%

2.3 Liquidity

A Current Ratio of 1.10 indicates that ZEPP should not have too much problems paying its short term obligations.

ZEPP has a Current ratio of 1.10. This is amonst the worse of the industry: ZEPP underperforms 87.10% of its industry peers.

A Quick Ratio of 0.77 indicates that ZEPP may have some problems paying its short term obligations.

Looking at the Quick ratio, with a value of 0.77, ZEPP is doing worse than 87.90% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.1
Quick Ratio	0.77

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ZEPP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -172.73%.

ZEPP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -18.93%.

Measured over the past years, ZEPP shows a very negative growth in Revenue. The Revenue has been decreasing by -26.33% on average per year.

EPS 1Y (TTM)-172.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

Revenue 1Y (TTM)-18.93%

Revenue growth 3Y-42.67%

Revenue growth 5Y-26.33%

Sales Q2Q%46.18%

3.2 Future

The Earnings Per Share is expected to grow by 32.82% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 31.50% on average over the next years. This is a very strong growth

EPS Next Y43.41%

EPS Next 2Y32.82%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next Year37.49%

Revenue Next 2Y31.5%

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZEPP. In the last year negative earnings were reported.

Also next year ZEPP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ZEPP's earnings are expected to grow with 32.82% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.82%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ZEPP does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZEPP HEALTH CORP-ADR

NYSE:ZEPP (11/4/2025, 9:46:03 AM)

37.5

-1.4 (-3.6%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupTechnology Hardware & Equipment

GICS IndustryElectronic Equipment, Instruments & Components

Earnings (Last)08-03 2025-08-03/bmo

Earnings (Next)11-04 2025-11-04/amc

Inst Owners29.96%

Inst Owner Change-24.98%

Ins Owners5.91%

Ins Owner ChangeN/A

Market Cap2.25B

Revenue(TTM)200.00M

Net Income(TTM)-77867000

Analysts82.86

Price Target60.96 (62.56%)

Short Float %9.14%

Short Ratio1.75

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.78%

PT rev (3m)385.07%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-51.08%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)4.03%

Revenue NY rev (3m)15.31%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	11.25
P/FCF	N/A
P/OCF	N/A
P/B	10
P/tB	11.17
EV/EBITDA	N/A

EPS(TTM)-8.57

EYN/A

EPS(NY)-0.37

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS3.33

BVpS3.75

TBVpS3.36

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-14.18%
ROE	-34.61%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	37.59%
FCFM	N/A

ROA(3y)-8.27%

ROA(5y)-3.78%

ROE(3y)-16.67%

ROE(5y)-7.49%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y22.57%

GM growth 5Y8.78%

F-ScoreN/A

Asset Turnover0.36

Health

		Industry Rank	Sector Rank
Debt/Equity	0.85
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.1
Quick Ratio	0.77
Altman-Z	4.47

F-ScoreN/A

WACC6.98%

ROIC/WACCN/A

Cap/Depr(3y)22.81%

Cap/Depr(5y)96.65%

Cap/Sales(3y)0.51%

Cap/Sales(5y)0.74%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-172.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%25%

EPS Next Y43.41%

EPS Next 2Y32.82%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-18.93%

Revenue growth 3Y-42.67%

Revenue growth 5Y-26.33%

Sales Q2Q%46.18%

Revenue Next Year37.49%

Revenue Next 2Y31.5%

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-91.73%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year49.29%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-162.93%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-156.9%

OCF growth 3YN/A

OCF growth 5YN/A

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

ChartMill assigns a fundamental rating of 2 / 10 to ZEPP.

Can you provide the valuation status for ZEPP HEALTH CORP-ADR?

ChartMill assigns a valuation rating of 1 / 10 to ZEPP HEALTH CORP-ADR (ZEPP). This can be considered as Overvalued.

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?

ZEPP HEALTH CORP-ADR (ZEPP) has a profitability rating of 2 / 10.

ZEPP HEALTH CORP-ADR (ZEPP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ZEPP HEALTH CORP-ADR / ZEPP FAQ

What is the fundamental rating for ZEPP stock?

Can you provide the valuation status for ZEPP HEALTH CORP-ADR?

Can you provide the profitability details for ZEPP HEALTH CORP-ADR?